JBI-589 is a non-covalent, isoform-selective inhibitor of peptidylarginine deiminase 4 (PAD4) with oral bioavailability, developed for preclinical cancer and immunology research. It reduces CXCR2 expression, blocks neutrophil chemotaxis, and has shown activity in reducing primary tumor growth and metastasis in experimental studies.
- Selective PAD4 inhibition with demonstrated activity in cellular assays.
- Orally bioavailable small molecule suitable for in vivo studies.
- High chemical purity for research use.
- Soluble in DMSO at high concentrations (requires sonication).
- Stable when stored under recommended powder and solvent conditions.